



## **Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting**

May 1, 2018

**CAMBRIDGE, Mass., April 30, 2018** – [Gamida Cell](#), a leading cellular and immune therapeutics company, today announced that data from the company's NiCord program will be presented during the International Society for Cellular Therapy (ISCT) Annual Meeting, held May 2-5 in Montreal.

Jaap Jan Boelens, M.D., Ph.D., clinical study investigator and pediatric oncologist/immunologist at the University Medical Centre Utrecht, in Utrecht, the Netherlands, will give an oral presentation of immune reconstitution data from Gamida Cell's phase I/II study of NiCord in high-risk hematologic malignancies.

**Title:** Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-expanded Cord Blood (NiCord) Transplantation

**Session:** Plenary Breakout 1 – iPSC and Organogenesis; Room 519AB

**Date:** Saturday, May 5, 2018, 3:15-4:30 p.m. ET

Mitchell Horwitz, M.D., principal investigator and professor of medicine at the Duke Cancer Institute, Durham, NC, will share key clinical findings from the phase I/II NiCord study during a session on the current status of cord blood transplantation.

**Title:** Current Status of Cord Blood Transplantation

**Session:** ISCT-CBA Cord Blood Series Session 1; Room 518A

**Date:** Wednesday, May 2, 2018, 8:30-10:00 a.m. ET

### **About NiCord**

NiCord, the company's lead clinical program, is under development as a universal bone marrow transplant solution for patients with high-risk hematologic malignancies. NiCord has demonstrated improved efficacy over unmanipulated cord blood, including fewer bacterial and fungal infections and a reduction in duration of hospital stays. NiCord has been granted breakthrough status by the U.S. Food and Drug Administration, making it the first bone marrow transplant alternative to receive this designation. It has also received U.S. and EU orphan drug designation. A phase III study evaluating NiCord in patients with leukemia and lymphoma is ongoing in the United States, Europe and Asia (NCT02730299). For more information on NiCord clinical trials, please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

### **About Gamida Cell**

Gamida Cell is a leader in cellular and immune therapeutics dedicated to treating patients with cancer and rare genetic diseases. The company is building a diverse pipeline based on its proprietary NAM technology platform to deliver transformative medicines to patients in need of new treatment options. To learn more about Gamida Cell, including current clinical studies, please visit [gamida-cell.com](http://gamida-cell.com) and on [Twitter](#), [LinkedIn](#) and [Facebook](#).

### **Contact:**

Katie Engleman  
Pure Communications  
[katie@purecommunications.com](mailto:katie@purecommunications.com)  
+1 910.509.3977

### **Investor Contact:**

Daniel Ferry  
LifeSci Advisors  
[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)  
+1 617.535.7746